MedTrace Logo

Biomarkerscreening in Cervical Cancer and Its Preinvasive Lesions

NCT02238990 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-05-31

No results posted yet for this study

Summary

The following trial is a multicenter and prospective research trial of the colposcopy unit of luebeck university and the national research center in Borstel, Germany.

The study is to identify and evaluate new biomarkers in human papilloma virus (HPV) associated malignancies and its preinvasive lesions of the cervix uteri. Fresh tissue samples being removed during conizations and/or hysterectomies are to be fixed in HOPE's solution and analyzed according to their transcriptomes and methylosome. The hereby found candidates are to be validated using immunohistochemistry and RT \[real-time\] -PCR \[polymerase chain reaction\].

The project is meant to be followed by continuous studies developing a new test describing the malignant potential of HPV associated genital lesions.

Conditions

  • Evaluation of New Tissue Biomarkers for Cervical Cancer

Sponsors & Collaborators

  • University of Luebeck

    lead OTHER

Principal Investigators

  • Daniel Beyer, PD Dr. · University of Luebeck

  • Torsten Goldmann, Prof. Dr. · Forschungszentrum Borstel

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2030-12-01
Completion
2030-12-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02238990 on ClinicalTrials.gov